Adaptimmune Therapeutics
ADAP
ADAP was delisted on the 27th of October, 2025.
89 hedge funds and large institutions have $134M invested in Adaptimmune Therapeutics in 2023 Q2 according to their latest regulatory filings, with 34 funds opening new positions, 26 increasing their positions, 11 reducing their positions, and 10 closing their positions.
240% more first-time investments, than exits
New positions opened: 34 | Existing positions closed: 10
136% more repeat investments, than reductions
Existing positions increased: 26 | Existing positions reduced: 11
100% more funds holding in top 10
Funds holding in top 10: 1 → 2 (+1)
37% more funds holding
Funds holding: 65 → 89 (+24)
6% more capital invested
Capital invested by funds: $126M → $134M (+$7.47M)
5.85% less ownership
Funds ownership: 70.15% → 64.3% (-5.8%)
64% less call options, than puts
Call options by funds: $25K | Put options by funds: $70K
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
MAM
MPM Asset Management
Boston,
Massachusetts
|
+$7.5M |
| 2 |
MB
MPM BioImpact
Boston,
Massachusetts
|
+$6.08M |
| 3 |
TCM
Tang Capital Management
San Diego,
California
|
+$5.83M |
| 4 |
LFCM
Long Focus Capital Management
San Juan,
Puerto Rico
|
+$2.83M |
| 5 |
PHS
PFM Health Sciences
San Francisco,
California
|
+$2.82M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
ECM
Endurant Capital Management
San Mateo,
California
|
-$1M |
| 2 |
Bank of America
Charlotte,
North Carolina
|
-$839K |
| 3 |
Morgan Stanley
New York
|
-$209K |
| 4 |
VF
Virtu Financial
New York
|
-$96K |
| 5 |
SEI Investments
Oaks,
Pennsylvania
|
-$51.7K |
ADAP Hedge Fund Activity: Q2 2023 in Review
89 of the 6,383 institutional investors tracked by Wall St. Rank reported a position in Adaptimmune Therapeutics (ADAP) for Q2 2023, worth a combined $134M — up 5.9% from $126M a quarter earlier.
Buyers outnumbered sellers: 34 funds opened new ADAP positions and 10 closed out — a net gain of 24 holders — while 26 added to existing stakes and 11 trimmed.
The largest buyer was MPM Asset Management, opening a new position worth an estimated $7.5M. The largest seller was Endurant Capital Management, cutting an estimated $1M.
- 89 institutional investors held Adaptimmune Therapeutics (ADAP) as of Q2 2023, up from 65 in Q1 2023.
- Funds reported $134M of Adaptimmune Therapeutics stock for Q2 2023, up 5.9% quarter-over-quarter.
- 34 funds opened new Adaptimmune Therapeutics positions in Q2 2023 and 10 closed out, a net change of +24 holders.
- The largest Adaptimmune Therapeutics buyer in Q2 2023 was MPM Asset Management, an estimated $7.5M added.
- The largest Adaptimmune Therapeutics seller in Q2 2023 was Endurant Capital Management, an estimated $1M sold.
Based on aggregated 13F filings for Q2 2023.